Cargando…

Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy

Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jie, Fang, Huapan, Hu, Yingying, Wu, Jiayan, Zhang, Sijia, Feng, Yuanji, Lin, Lin, Tian, Huayu, Chen, Xuesi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379363/
https://www.ncbi.nlm.nih.gov/pubmed/34466725
http://dx.doi.org/10.1016/j.bioactmat.2021.05.036
_version_ 1783740989774495744
author Chen, Jie
Fang, Huapan
Hu, Yingying
Wu, Jiayan
Zhang, Sijia
Feng, Yuanji
Lin, Lin
Tian, Huayu
Chen, Xuesi
author_facet Chen, Jie
Fang, Huapan
Hu, Yingying
Wu, Jiayan
Zhang, Sijia
Feng, Yuanji
Lin, Lin
Tian, Huayu
Chen, Xuesi
author_sort Chen, Jie
collection PubMed
description Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumor immunotherapeutic strategy by combining mannosylated nanovaccines and gene regulated PD-L1 blockade for immune stimulation and killing activity. Here, we fabricate a mannose modified PLL-RT (Man-PLL-RT) mediated nanovaccines with dendritic cells (DCs) targeting capacity. Man-PLL-RT is capable of co-encapsulating with antigen (ovalbumin, OVA) and adjuvant (unmethylated cytosine-phosphate-guanine, CpG) by electrostatic interaction. This positively charged Man-PLL-RT/OVA/CpG nanovaccines can facilitate the endocytosis, maturation and cross presentation in DCs. However, the nanovaccines arouse limited inhibition of tumor growth, which is mainly due to the immunosuppressed microenvironment of tumors. Combining tumor nanovaccines with gene regulated PD-L1 blockade leads to an obvious tumor remission in B16F10 melanoma bearing mice. The collaborative strategy provides essential insights to boost the benefits of tumor vaccines by regulating the checkpoint blockade with gene therapy.
format Online
Article
Text
id pubmed-8379363
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher KeAi Publishing
record_format MEDLINE/PubMed
spelling pubmed-83793632021-08-30 Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy Chen, Jie Fang, Huapan Hu, Yingying Wu, Jiayan Zhang, Sijia Feng, Yuanji Lin, Lin Tian, Huayu Chen, Xuesi Bioact Mater Article Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge in exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumor immunotherapeutic strategy by combining mannosylated nanovaccines and gene regulated PD-L1 blockade for immune stimulation and killing activity. Here, we fabricate a mannose modified PLL-RT (Man-PLL-RT) mediated nanovaccines with dendritic cells (DCs) targeting capacity. Man-PLL-RT is capable of co-encapsulating with antigen (ovalbumin, OVA) and adjuvant (unmethylated cytosine-phosphate-guanine, CpG) by electrostatic interaction. This positively charged Man-PLL-RT/OVA/CpG nanovaccines can facilitate the endocytosis, maturation and cross presentation in DCs. However, the nanovaccines arouse limited inhibition of tumor growth, which is mainly due to the immunosuppressed microenvironment of tumors. Combining tumor nanovaccines with gene regulated PD-L1 blockade leads to an obvious tumor remission in B16F10 melanoma bearing mice. The collaborative strategy provides essential insights to boost the benefits of tumor vaccines by regulating the checkpoint blockade with gene therapy. KeAi Publishing 2021-06-04 /pmc/articles/PMC8379363/ /pubmed/34466725 http://dx.doi.org/10.1016/j.bioactmat.2021.05.036 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Chen, Jie
Fang, Huapan
Hu, Yingying
Wu, Jiayan
Zhang, Sijia
Feng, Yuanji
Lin, Lin
Tian, Huayu
Chen, Xuesi
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title_full Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title_fullStr Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title_full_unstemmed Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title_short Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
title_sort combining mannose receptor mediated nanovaccines and gene regulated pd-l1 blockade for boosting cancer immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379363/
https://www.ncbi.nlm.nih.gov/pubmed/34466725
http://dx.doi.org/10.1016/j.bioactmat.2021.05.036
work_keys_str_mv AT chenjie combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT fanghuapan combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT huyingying combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT wujiayan combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT zhangsijia combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT fengyuanji combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT linlin combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT tianhuayu combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy
AT chenxuesi combiningmannosereceptormediatednanovaccinesandgeneregulatedpdl1blockadeforboostingcancerimmunotherapy